GlassScriptPhysician profile
Marco Antonio Paez
NPI 1902167695
$4,808.56
in general payments reported to CMS, 2019-2025
31 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $201 · 2021: $907 · 2022: $856 · 2023: $1,123 · 2024: $575 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563 · Education: $29.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.22 |
| Education | $29.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $885.44 | 2019-2025 | |
| Madrigal Pharmaceuticals | $692.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $662.63 | 2020-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $342.92 | 2021-2023 | Stelara |
| Conmed Corporation | $308.44 | 2019-2020 | |
| Pfizer INC. | $223.26 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $193.12 | 2023-2025 | Dupixent |
| Cook Medical LLC | $168.94 | 2022 | |
| Lucid Diagnostics INC. | $145.05 | 2023 | |
| Endogastric Solutions, INC | $125.70 | 2022 | |
| Lilly USA, LLC | $125.00 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $121.04 | 2023 | Zeposia |
| Ardelyx, INC. | $104.45 | 2023-2025 | Ibsrela |
| Intuitive Surgical, INC. | $93.27 | 2022 | |
| Janssen Scientific Affairs, LLC | $78.30 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $75.22 | 2023-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $67.44 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $58.54 | 2020-2021 | |
| Genzyme Corporation | $45.92 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $44.65 | 2023 | Dificid |
| Braintree Laboratories, INC. | $41.21 | 2021 | |
| Mallinckrodt Hospital Products INC. | $32.54 | 2023 | Terlivaz |
| Celltrion USA INC. | $29.01 | 2024 | Zymfentra |
| Novo Nordisk INC | $23.31 | 2025 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $21.56 | 2023 | Entyvio |
| Astrazeneca Pharmaceuticals LP | $21.16 | 2023 | Andexxa |
| Sanofi-Aventis U.S. LLC | $19.12 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $15.87 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $15.35 | 2023 | Ocaliva |
| Capsovision, INC. | $14.01 | 2023 | Capsocam Plus |
| Redhill Biopharma INC. | $13.65 | 2023 | Talicia, Movantik, Aemcolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Paez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.